drugset / Trial / NCT01795313
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
Phase 1
Terminated
23 enrolled
James Felker
National Cancer Institute (NCI) · collabSolving Kids' Cancer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.
Timeline
- Start
- 2012-08
- Primary completion
- 2025-12-03
- Completion
- 2025-12-03
Outcome
Outcome not reported
Stopped (Enrollment): “Closed supratentorial arm prematurely secondary to lack of enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLA-A2 restricted synthetic tumor antigen | Vaccine | — | — |
| Background | Imiquimod | Other / unclassified | — | — |